Hepatocellular carcinoma (hcc) is the sixth most common cancer, and the
third most common cause of cancer-related death worldwide. major causes of
hcc includes hepatitis b (hbv), hepatitis c (hcv), alcoholic liver disease, and possibly nonalcoholic steatohepatitis. both hbv and hcv have been declared to be carcinogenic to humans by the international agency for research on cancer (iarc). it has reported that tamoxifen (tam) can inhibit proliferation and induce apoptosis in many cancers such as breast cancer cell, gastric cancer bgc823 cell, sk-hep-1 hepatoblasma cells and human cholangiocarcinoma cells. previously, we reported that tam induced significant apoptosis in hepatocellular carcinoma plc/prf/5 cell line. with regard to our previous result, the aim of the present study was to analyze the apoptotic and the antiprolifrative effects of tam in the hepatocellular carcinoma hepg2 cell line.
Methods
Materials and methods: the cells were treated with various concentrations of tam (1, 5, 10, 25, 50, 75, and 100 μm/lit) and the mtt assay was used to determine the cell viability and then cells were treated with a single dose of tam (25μm based on ic50 values) and flow cytometry assay was performed to assess apoptotic cells.
Results
Results: tam inhibited the growth of hepg2 cells and induced apoptosis significantly with a time- and dose-dependent manner.
our finding clearly indicated that tam has a significant inhibitory effect and
induces apoptosis with a dose- and time-dependent manner.
Conclusion
Tam can significantly inhibit the growth of hepg2 cells and plays a
significant role in apoptosis induction of this cell line
